Search

everythinglearnresearchcommunity

for

Search:↓

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.

User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

The user is experiencing hair shedding after using a multipeptide hair growth serum and is concerned about losing baby hair. They are questioning whether they should stop using the serum due to this shedding.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Exosomes from Musely are being discussed as a topical hair loss treatment containing ingredients like latanoprost, caffeine, cetirizine, melatonin, vitamin D3, vitamin E, and biotin. Users are curious about its effectiveness and potential side effects, noting it may take 4-6 months to see results.

The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

A user with PCOS experienced hair loss and found success using a triple dose of O.N.E Omega by Pure Encapsulations after discovering low Omega fatty acids. Biotin provided minimal improvement, but the Omega supplement significantly restored hair.

User tried finasteride and minoxidil for hair loss, now considering exosomes injections. Will update on results after appointment.

Exosome therapy for hair loss is being discussed, with mixed personal experiences and no significant results reported by some users. The treatment is expensive, and users are skeptical about its effectiveness.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user shared their hair restoration journey using oral and topical finasteride, experiencing side effects with the former. They later switched to microneedling, scalp massages, and vitamins (D3, Zinc, Biotin, B complex, Vitamin E) with mixed feedback on progress.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

User experienced positive results with CosmeRNA for hair loss after 1.5 weeks, including reduced scalp itchiness, less oiliness, and decreased shedding. They have not felt any side effects and are happy with the treatment so far.